drugset
drugset / Trial / NCT01594268

A Prospective, Open Label Study of CERtican in KIdney Transplantation

NCT01594268 ↗

Phase 4 Completed 54 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

A prospective, open label study of CERtican in KIdney transplantation

Timeline

Start
2012-03
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule — —

Indications

No indication recorded.